ArticleBMC ophthalmology2019
XEN® stent complications: a case series.
Article in BMC ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Enabling adaptability and hydraulic resistance in minimally invasive glaucoma surgery using an architecture-driven approach.iScience · 2026Article
- Efficacy and Safety of Ab-externo Approach versus Ab-interno Approach of XEN45 Gel Stent Implantation: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Long-Term Morphological Changes of Crosslinked Gelatin Stent.Clinical & experimental ophthalmology · 2025Article
- Management of fracture and displacement of a previously successful bilateral transconjunctival ab-externo XEN gel stent: a case report.BMC ophthalmology · 2025Article
- [Real-world outcomes of glaucoma surgical procedures for open-angle glaucoma].Die Ophthalmologie · 2023Review
- The use of polyisobutylene-based polymers in ophthalmology.Bioactive materials · 2022Article
- PreserFlo MicroShunt® exposure: a case series.BMC ophthalmology · 2021Article
- XEN Gel Staining with Trypan Blue: A Simple and Effective Technique to Improve Device Visualization during Implantation.Journal of current glaucoma practiceArticle
- How to Rescue of the Dislocated XENJournal of current ophthalmologyArticle
- Ethics of Glaucoma Widgets.Journal of current glaucoma practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundXEN® gel stent (Allergan, Dublin/Republic of Ireland) is a relatively new microinvasive glaucoma device providing an ab-interno approach to the subconjunctival space for aqueous drainage and reduction of intraocular pressure. It is thought to be less invasive, reduce surgical time and post-operative infection rates compared with traditional glaucoma procedures. Little information however, has been published regarding complications and subsequent management. CASE PRESENTATION: The authors highlight five complicated cases of XEN® stent insertion, how they were managed and key learning points. Cases include: entire stent found at the bottom of the anterior chamber several months after uncomplicated insertion, stent broke into multiple pieces during manipulation within subconjunctiva, XEN45 stent migrated into the anterior chamber 7 months post-operatively and a case of limbal-based conjunctival dissection during open revision which lead to additional scarring around the stent and subsequent raised intraocular pressure.
conclusionsWe present some new and interesting complications of XEN implant as well as potential management options. This can assist clinical decision-making and enable better pre-operative discussions with patients regarding risks of surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.